EC Number |
Recommended Name |
Source Tissue |
Reference |
---|
1.17.3.2 | xanthine oxidase |
vein |
- |
684354 |
1.2.1.3 | aldehyde dehydrogenase (NAD+) |
vein |
- |
697280, 697845 |
2.7.1.137 | phosphatidylinositol 3-kinase |
vein |
- |
708145 |
2.7.11.30 | receptor protein serine/threonine kinase |
vein |
- |
705441 |
4.4.1.1 | cystathionine gamma-lyase |
vein |
- |
690376 |
3.4.14.5 | dipeptidyl-peptidase IV |
vein |
in vein DPIV represents 80% of the total Gly-L-Pro-4-nitroanilide-hydrolyzing activity |
697386 |
3.1.3.53 | [myosin-light-chain] phosphatase |
vein |
mesenteric vein, high expression of enzyme with predominance of 3-exon-excluded, leucine-zipper negative MYPT 1 isoform |
663585 |
1.15.1.1 | superoxide dismutase |
vein |
saphenous veins |
675625 |
3.4.17.23 | angiotensin-converting enzyme 2 |
vein |
total vessel wall expression of ACE and ACE2 is similar during all stages of atherosclerosis. The observed ACE2 protein is enzymatically active and activity is lower in the stable advanced atherosclerotic lesions, compared to early and ruptured atherosclerotic lesions |
693806 |